Table 2 The comparison of baseline characteristics between the CR and non-CR groups
| Baseline characteristics | CR group | Non-CR group | p value | ||
|---|---|---|---|---|---|
| Number of cases | N | 13 | 13 | ||
| Age |
Median (min–max) | 53 (25–68) | 23 (16–70) | 0.09 | |
| Gender—male | N (%) | 4 | 7 | 0.234 | |
| Body weight, kg |
Median (min–max) |
47 (43.7–68.2) |
55 (37.7–83.3) | 0.48 | |
| Duration of disease, month |
Median (min–max) |
118 (12–159) |
28 (6–130) | 0.001 | |
| Extent of UC (Montreal classification) | 0.42 | ||||
| left side colitis (E2) | N | 4 | 6 | ||
| pancolitis (E3) | N | 9 | 7 | ||
| Disease activity | |||||
| pMayo score |
Median (IQR) |
6 (6–7) |
7 (5–7) | 0.76 | |
| MES |
Median (IQR) |
2 (2–2) |
2 (2–3) | 0.03 | |
| Concomitant medication | |||||
| 5-aminosalicylic acid | N (%) | 12 | 10 | ||
| Corticosteroid | N (%) | 4 | 3 | 0.658 | |
| Immunosuppressant | N (%) | 5 | 8 | 0.239 | |
| Anti-TNF-alpha agent | N (%) | 3 | 2 | 0.619 | |
| Biomarker at entry | |||||
| FC (mg/kg) |
Median (IQR) |
15,669 (7280–20,017) |
9496 (1073–14,015) | 0.07 | |
| WBC count |
Median (IQR) |
5980 (4760–6970) |
7290 (5200–8250) | 0.29 | |
| CRP (mg/dL) |
Median (IQR) |
0.66 (0.1–4.56) |
0.36 (0.1–1.26) | 0.53 | |